QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.106.114330v1 320/2/552    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Best, J. D. Articles by Shearman, M. S. Search for Related Content PubMed PubMed Citation Articles by Best, J. D. Articles by Shearman, M. S.

NEUROPHARMACOLOGY

The Novel Secretase Inhibitor N-[cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) Reduces Amyloid Plaque Deposition without Evidence of Notch-Related Pathology in the Tg2576 Mouse

Departments of In Vivo Neuroscience (J.D.B., J.R.A.), Molecular and Cellular Neuroscience (D.W.S., R.O., H.D.L., S.E., N.W., T.W.R., M.S.S.), and Chemistry (M.A.R., I.C., T.H.), Merck Sharp and Dohme, Neuroscience Research Centre, Harlow, United Kingdom; and Department of Safety Assessment (C.B.-L., P.A.L.), Merck Sharp and Dohme Research Centre, Clermont-Ferrand, France

There is a substantial body of evidence indicating that -amyloid peptides (A) are critical factors in the onset and development of Alzheimer's disease (AD). One strategy for combating AD is to reduce or eliminate the production of A through inhibition of the -secretase enzyme, which cleaves A from the amyloid precursor protein (APP). We demonstrate here that chronic treatment for 3 months with 3 mg/kg of the potent, orally bioavailable and brain-penetrant -secretase inhibitor N-[cis-4-[(4-chlorophenyl)-sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) attenuates the appearance of amyloid plaques in the Tg2576 mouse. These reductions in plaques were also accompanied by a decrease in the level of reactive gliosis. The morphometric and histological measures agreed with biochemical analysis of A(40) and A(42) in the cortex. Interestingly, the volume of the plaques across treatment groups did not change, indicating that reducing A levels does not significantly alter deposit growth once initiated. Furthermore, we demonstrate that these beneficial effects can be achieved without causing histopathological changes in the ileum, spleen, or thymus as a consequence of blockade of the processing of alternative substrates, such as the Notch family of receptors. This indicates that in vivo a therapeutic window between these substrates seems possible—a key concern in the development of this approach to AD. An understanding of the mechanisms whereby MRK-560 shows differentiation between the APP and Notch proteolytic pathway of -secretase should provide the basis for the next generation of -secretase inhibitors.

Address correspondence to: Dr. Jonathan Best, DanioLabs Ltd., Unit 7330, Cambridge Research Park, Waterbeach, Cambridgeshire, CB5 9TN, UK. E-mail: jonathan.best{at}daniolabs.com

This article has been cited by other articles:

				R. A. Karlnoski, A. Rosenthal, D. Kobayashi, J. Pons, J. Alamed, M. Mercer, Q. Li, M. N. Gordon, P. E. Gottschall, and D. Morgan Suppression of Amyloid Deposition Leads to Long-Term Reductions in Alzheimer's Pathologies in Tg2576 Mice J. Neurosci., April 15, 2009; 29(15): 4964 - 4971. [Abstract] [Full Text] [PDF]

				M. E. Mullendore, J.-B. Koorstra, Y.-M. Li, G. J. Offerhaus, X. Fan, C. M. Henderson, W. Matsui, C. G. Eberhart, A. Maitra, and G. Feldmann Ligand-dependent Notch Signaling Is Involved in Tumor Initiation and Tumor Maintenance in Pancreatic Cancer Clin. Cancer Res., April 1, 2009; 15(7): 2291 - 2301. [Abstract] [Full Text] [PDF]

				D. Abramowski, K.-H. Wiederhold, U. Furrer, A.-L. Jaton, A. Neuenschwander, M.-J. Runser, S. Danner, J. Reichwald, D. Ammaturo, D. Staab, et al. Dynamics of A{beta} Turnover and Deposition in Different {beta}-Amyloid Precursor Protein Transgenic Mouse Models Following {gamma}-Secretase Inhibition J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 411 - 424. [Abstract] [Full Text] [PDF]

				D. T. Teachey, A. E. Seif, V. I. Brown, M. Bruno, R. M. Bunte, Y. J. Chang, J. K. Choi, J. D. Fish, J. Hall, G. S. Reid, et al. Targeting Notch signaling in autoimmune and lymphoproliferative disease Blood, January 15, 2008; 111(2): 705 - 714. [Abstract] [Full Text] [PDF]

				R. M. Page, K. Baumann, M. Tomioka, B. I. Perez-Revuelta, A. Fukumori, H. Jacobsen, A. Flohr, T. Luebbers, L. Ozmen, H. Steiner, et al. Generation of A 38 and A 42 Is Independently and Differentially Affected by Familial Alzheimer Disease-associated Presenilin Mutations and {gamma}-Secretase Modulation J. Biol. Chem., January 11, 2008; 283(2): 677 - 683. [Abstract] [Full Text] [PDF]

				B. P. Imbimbo, E. Del Giudice, D. Colavito, A. D'Arrigo, M. D. Carbonare, G. Villetti, F. Facchinetti, R. Volta, V. Pietrini, M. F. Baroc, et al. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic Acid (CHF5074), a Novel {gamma}-Secretase Modulator, Reduces Brain beta-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease without Causing Peripheral Toxicity J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 822 - 830. [Abstract] [Full Text] [PDF]

				G. R Seabrook, W. J. Ray, M. Shearman, and M. Hutton BEYOND AMYLOID: The Next Generation of Alzheimer's Disease Therapeutics Mol. Interv., October 1, 2007; 7(5): 261 - 270. [Abstract] [Full Text] [PDF]